A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
Robert JonesRuth PlummerVictor MorenoLouise CarterDesamparados RodaElena GarraldaRebecca S KristeleitDebashis SarkerHendrick-Tobias ArkenauPatricia RoxburghHarriet Sarah WalterSarah P BlagdenAlan AnthonyBarbara J KlenckeMark M KowalskiUdai BanerjiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
SRA737 in combination with low-dose gemcitabine was well tolerated with lower myelotoxicity than has been seen at standard doses of gemcitabine or with other combinations of Chk1 inhibitors with gemcitabine. Tumor responses were observed in anogenital and other solid tumors.